Home | Publications | Company Information | Top 50 Pharma | Tadeka place holder
place holder place holder

Tadeka

Takeda: PharmaVitae Profile

PharmaVitae Profile

Publication Date   October 2006
Publisher   Datamonitor
Product Type   Report
Pages   156
ISBN Number   not applicable
Product Code   DAT570
Ask a question about this product?

Price £3,000.00

approximately: $5,605 | €3,805

Summary


Introduction

This analysis examines the historical and forecast performance for Takeda in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark Takeda's performance against key rivals in the ethical pharmaceutical sector
  • Analyze Takeda's performance out to 2011 in light of the wave of M&A activity that has swept across the Japanese pharmaceutical market
  • Assess whether Takeda can restructure its portfolio to drive long-term growth and counteract forecast declining revenues for its key drug franchises

Content


  • Chapter 1 Executive Summary
    • Key findings
    • Historical and forecast ethical sales performance
    • Therapeutic strategy
    • Launch and expiry outlook
    • Externalization, geographic and molecule type strategies
    • Externalization strategy
    • Geographic strategy
    • Molecule type strategy
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • Chapter 2 Corporate History
    • Key findings
    • Background
    • Key corporate developments
    • Pharmaceuticals
    • TAP: a gateway into the US market...
    • Consumer health
    • Joint ventures
    • M&A history
    • Acquisition of Syrrx
    • M&A strategy
    • Current corporate structure
    • Pharmaceuticals
    • Consumer health
    • Macro environmental analysis
    • Current position of the healthcare system
    • Western competition, a call to action...
    • Medium-term management plan
    • Current position
    • Current management team
  • Chapter 3 Historical Performance
    • Key findings
    • Introduction
    • Revenue and growth rate analysis, 2002-05
    • Revenue and growth rate vs. peer set
    • Product analysis, 2002-05
    • Growth drivers
    • Actos
    • Blopress
    • Growth resistors
    • Prevacid
    • Lupron
    • Operating revenue and cost analysis, 2002-05
    • Operating revenue/cost analysis
  • Chapter 4 Forecast Performance
    • Key findings
    • Introduction
    • Revenue and growth rate, 2005-11
    • Product analysis, 2005-11
    • Key growth drivers
    • Blopress
    • Tavocept
    • TAK-242
    • TAK-475
    • Key growth resistors
    • Prevacid
    • Actos
    • Lupron/Enantone
    • Calslot
    • Therapy area analysis, 2005-11
    • Key growth drivers
    • Cardiovascular
    • Oncology
    • CNS
    • Diabetes & endocrinology
    • Key growth resistors
    • Gastrointestinal
    • Therapy area focus
    • Launches and expiries analysis, 2005-11
    • Launch portfolio
    • Core portfolio
    • Expiry portfolio
    • Launch/core/expiry configuration
    • Externalization analysis, 2005-11
    • Geographic analysis, 2005-11
    • Molecule type analysis, 2005-11
  • Chapter 5 Key Products And Competitors
    • Key findings
    • Overview
    • Diabetes & endocrinology
    • Actos
    • Overview
    • Sales forecast
    • News flow
    • ACTOplus met
    • Overview
    • Sales forecast
    • News flow
    • Competitive landscape
    • Basen
    • Overview
    • Sales forecast
    • Competitive landscape
    • Key diabetes & endocrinology competitors
    • Actos: Avandia duopoly
    • Patent expiry and generic invasion...
    • Market share errosion inevitable as new products enter the market ...
    • Cardiovascular
    • Blopress
    • Overview
    • Sales forecast
    • News flow
    • Competitive landscape
    • TAK-475
    • Overview
    • Sales forecast
    • Competitive landscape
    • Gastrointestinal
    • Prevacid
    • Overview
    • Sales forecast
    • News flow
    • Competitive landscape
    • Amitza
    • Overview
    • Sales forecast
    • News flow
    • Competitive landscape
  • Tak-390mr
    • Overview
    • Sales forecast
    • News flow
    • Competitive landscape
    • Key cardiovascular competitors
    • Oncology
    • Lupron
    • Overview
    • Sales forecast
    • Competitive landscape
    • Tavocept
    • Overview
    • Sales forecast
    • News flow
    • Competitive landscape
    • CNS
    • Rozerem
    • Overview
    • Sales forecast
    • News flow
    • Competitive landscape
    • Infectious disease
    • TAK-242
    • Overview
    • Sales forecast
    • News flow
    • Competitive landscape
    • AIID
    • Enbrel
    • Overview
    • Sales forecast
    • News flow
    • Competitive landscape
    • R&D pipeline
  • Chapter 6 Appendix
    • IMS vs. company-reported data reconciliation
    • Abbreviations
    • Exchange rates
  • List of Tables
    • Table 1: Executive management
    • Table 2: Peer set overview
    • Table 3: Operating revenue/cost analysis ($m), 2002-05
    • Table 4: Operating cost ratio analysis (% of total revenues), 2002-05
    • Table 5: Product portfolio overview ($m), 2005-11
    • Table 6: Therapy area overview, sales ($m), 2005-11
    • Table 7: Launch portfolio overview, sales ($m), 2005-11
    • Table 8: Core portfolio overview, sales ($m), 2005-11
    • Table 9: Expiry portfolio overview, sales ($m), 2005-11
    • Table 10: Externalization strategy overview
    • Table 11: Molecule type overview, sales ($m), 2005-11
    • Table 12: Key products overview
    • Table 13: Actos: overview
    • Table 14: Actos: sales forecast ($m), 2005-11
    • Table 15: Actos: news flow
    • Table 16: ACTOplus met: overview
    • Table 17: ACTOplus met: sales forecast ($m), 2005-11
    • Table 18: ACTOplus met: news flow
    • Table 19: Basen: overview
    • Table 20: Basen: sales forecast ($m), 2005-11
    • Table 21: Blopress: overview
    • Table 22: Blopress: sales forecast ($m), 2005-11
    • Table 23: Blopress: news flow
    • Table 24: TAK-475: overview
    • Table 25: TAK-475: sales forecast ($m), 2005-11
    • Table 26: Prevacid: overview
    • Table 27: Prevacid: sales forecast ($m), 2005-11
    • Table 28: Prevacid: news flow
    • Table 29: Amitza: overview
    • Table 30: Amitza: sales forecast ($m), 2005-11
    • Table 31: Amitza: news flow
    • Table 32: TAK-390MR: overview
    • Table 33: TAK-390MR sales forecast ($m), 2005-11
    • Table 34: TAK-390MR: news flow
    • Table 35: Lupron: overview
    • Table 36: Lupron: sales forecast ($m), 2005-11
    • Table 37: Tavocept: overview
    • Table 38: Tavocept: sales forecast ($m), 2005-11
    • Table 39: Tavocept: news flow
    • Table 40: Rozerem: overview
    • Table 41: Rozerem: sales forecast ($m), 2005-11
    • Table 42: Rozerem: news flow
    • Table 43: TAK-242: overview
    • Table 44: TAK-242: sales forecast ($m), 2005-11
    • Table 45: TAK-242: news flow
    • Table 46: Enbrel: overview
    • Table 47: Enbrel: sales forecast ($m), 2005-11
    • Table 48: Enbrel: news flow
    • Table 49: Takeda's R&D pipeline (Phase I-registration)
    • Table 50: Exchange rates, 2005
  • List of Figures
    • Figure 1: Historical and forecast ethical sales performance, Takeda vs. Peer set (% CAGR)
    • Figure 2: Therapeutic focus vs. peer set (%)
    • Figure 3: Launch, core and expiry, Takeda, absolute sales growth, 2005-11 (sales as % of 2005 sales)
    • Figure 4: Launch, core and expiry, peer set, absolute sales growth, 2005-11 (sales as % of 2005 sales)
    • Figure 5: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2005
    • Figure 6: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2011
    • Figure 7: SWOT analysis: Takeda
    • Figure 8: Corporate structure
    • Figure 9: Corporate structure - current performance
    • Figure 10: Revenue & growth rate (ethical sales) ($m), 2002-05
    • Figure 11: Ethical revenue ($m) and growth rate (%) vs. peer set, 2002-05
    • Figure 12: Growth drivers/resistor products of historical revenue performance ($m), 2002-05
    • Figure 13: Operating revenue/cost analysis ($m), 2002-05
    • Figure 14: Operating cost ratio analysis (% of total revenues), 2002-05
    • Figure 15: Operating cost ratio vs. peer set, 2002-05
    • Figure 16: Ethical revenue ($m) and growth rate (%), 2005-11
    • Figure 17: Top five products by ethical sales, 2005
    • Figure 18: Top five products by ethical sales, 2011
    • Figure 19: Growth drivers and resistors by product, 2005-11
    • Figure 20: Key strategic products, sales ($m), 2005-11
    • Figure 21: Ethical sales by therapy area ($m), 2005-11
    • Figure 22: Growth drivers and resistors by therapy area (%), 2005-11
    • Figure 23: Ethical sales by therapy area (%), 2005-11
    • Figure 24: Therapy area focus compared with peer set (% total ethical sales), 2005
    • Figure 25: Therapy area focus compared with peer set (% total ethical sales), 2011
    • Figure 26: Launch schedule, sales ($m), 2005-11
    • Figure 27: Core products sales growth ($m), 2005-11
    • Figure 28: Expiry schedule, sales ($m), 2005-11
    • Figure 29: Launch, core and expiry, sales ($m), 2005-11
    • Figure 30: Launch, core and expiry (% of 2005 sales), Takeda, 2005-11
    • Figure 31: Launch, core and expiry (% of 2005 sales), peer set, 2005-11
    • Figure 32: Externalization dependency, sales ($m), 2005-11
    • Figure 33: Growth drivers and resistors, externally vs. internally discovered products, sales ($m), 2005-11
    • Figure 34: Externalization dependency vs. peer set, % total sales, 2005
    • Figure 35: Externalization dependency vs. peer set, % total sales, 2011
    • Figure 36: Geographical sales breakdown ($m), 2005-11
    • Figure 37: Growth drivers and resistors by geography, sales ($m), 2005-11
    • Figure 38: US dependency vs. peer set, % total sales, 2005
    • Figure 39: US dependency vs. peer set, % total sales, 2011
    • Figure 40: Molecule type sales breakdown($m), 2005-11
    • Figure 41: Growth drivers and resistors by molecule type, sales ($m), 2005-11
    • Figure 42: Biologics dependency vs. peer set, % total sales, 2005
    • Figure 43: Biologics dependency vs. peer set, % total sales, 2011
    • Figure 44: Direct competition for Actos
    • Figure 45: Direct competition for Prevacid
    • Figure 46: IMS vs. company-reported ethical sales discrepancy ($m), 2005
    • Figure 47: IMS vs. company-reported ethical sales forecast growth rates (%), 2005-11